Eiger BioPharmaceuticals, Inc. | Business Contracts

Second Amendment to Lease, dated February 16, 2023, by and between Eiger BioPharmaceuticals, Inc. and the McDonald Family Co. LLC (Filed With SEC on March 17, 2023)

Offer Letter Agreement, dated as of January 9, 2023, by and between Eiger BioPharmaceuticals, Inc. and David Apelian (Filed With SEC on March 17, 2023)

Separation Agreement and General Release, dated as of February 6, 2023, by and between Eiger BioPharmaceuticals, Inc. and David A. Cory (Filed With SEC on March 17, 2023)

Common Stock Purchase Agreement (Filed With SEC on June 7, 2022)

License Agreement, dated as of April 20, 2016, by and between Eiger BioPharmaceuticals, Inc. and Bristol-Myers Squibb Company (Filed With SEC on March 9, 2021)

Collaboration and Supply Agreement, dated May 15, 2018, by and between Eiger BioPharmaceuticals, Inc. and The Progeria Research Foundation (Filed With SEC on March 9, 2021)

Loan and Security Agreement (Filed With SEC on June 7, 2022)

Open Market Sale AgreementSM, dated March 25, 2022, by and between Eiger BioPharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on March 25, 2022)

Amendment No. 4 to Loan and Security Agreement, dated March 10, 2020, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (Filed With SEC on March 10, 2022)

Offer Letter Agreement, by and between Eiger BioPharmaceuticals, Inc. and Erik Atkisson, dated as of August 26, 2021 (Filed With SEC on November 4, 2021)

Amendment No. 6 to Loan and Security Agreement, dated October 6, 2021, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (Filed With SEC on November 4, 2021)

2021 Inducement Plan (Filed With SEC on August 5, 2021)

Form of Restricted Stock Unit Award Grant Notice and Award Agreement under 2013 Equity Incentive Plan (Filed With SEC on May 6, 2021)

Amendment No. 5 to Loan and Security Agreement, dated February 23, 2021, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (Filed With SEC on March 9, 2021)

Amendment No. 7 to License Agreement, dated November 3, 2020, by and between Eiger BioPharmaceuticals, Inc. and Merck Sharp & Dohme Corp (Filed With SEC on March 9, 2021)

Asset Purchase Agreement, by and between Eiger BioPharmaceuticals, Inc. and AbbVie Inc., dated as of November 20, 2020 (Filed With SEC on March 9, 2021)

Amendment No. 6 to License Agreement, dated September 3, 2010, by and between Eiger BioPharmaceuticals, Inc. and Merck Sharp & Dohme Corp (Filed With SEC on March 9, 2021)

License Agreement, dated September 3, 2010, by and between Eiger BioPharmaceuticals, Inc. and Merck Corporation (Filed With SEC on March 9, 2021)

Asset Purchase Agreement, dated September 25, 2015, by and between Eiger BioPharmaceuticals, Inc. and Tracey McLaughlin and Colleen Craig (Filed With SEC on March 9, 2021)

Amendment No. 1, dated June 15, 2020, to the Collaboration and Supply Agreement, dated May 15, 2018, by and between Eiger BioPharmaceuticals, Inc. and the Progeria Research... (Filed With SEC on August 6, 2020)

Open Market Sale AgreementSM, dated August 6, 2020, between Eiger BioPharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on August 6, 2020)

Eiger BioPharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (Filed With SEC on May 7, 2020)

Offer Letter Agreement, by and between the Registrant and Eldon Mayer, dated as of December 3, 2019 (Filed With SEC on May 7, 2020)

Description of Registrants Securities (Filed With SEC on March 13, 2020)

Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger Biopharmaceuticals, Inc. and Stephana E. Patton (Filed With SEC on November 7, 2019)

License Agreement, dated as of May 10, 2019, by and among the Trustees of the University of Pennsylvania and The Childrens Hospital of Philadelphia and Eiger Biopharmaceuticals,... (Filed With SEC on November 7, 2019)

Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger Biopharmaceuticals, Inc. and James Shaffer (Filed With SEC on November 7, 2019)

Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger Biopharmaceuticals, Inc. and Sriram Ryali (Filed With SEC on November 7, 2019)

Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger Biopharmaceuticals, Inc. and David A. Cory (Filed With SEC on November 7, 2019)

Offer Letter, dated as of February 26, 2019, by and between Eiger BioPharmaceuticals, Inc. and Stephana Patton (Filed With SEC on May 9, 2019)

Eiger BioPharmaceuticals, Inc. Non-Employee Director Compensation Policy, amended on May 7, 2019 (Filed With SEC on May 9, 2019)

Third Amendment to Loan and Security Agreement, dated March 5, 2019, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (Filed With SEC on May 9, 2019)

Offer Letter, dated as of November 30, 2018, by and between Eiger BioPharmaceuticals, Inc. and Sriram Ryali (Filed With SEC on May 9, 2019)

Underwriting Agreement, dated April 17, 2019 (Filed With SEC on April 22, 2019)

First Amendment to Loan and Security Agreement, dated August 24, 2017, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (Filed With SEC on March 14, 2019)

Separation Agreement dated as of November 30, 2018, by and between Eiger BioPharmaceuticals, Inc. and James Welch (Filed With SEC on March 14, 2019)

Eiger BioPharmaceuticals, Inc. (36)